Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes combo drug put to the test – but trial on hold

NCT ID NCT07433062

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is studying whether an experimental drug called AZD6793 changes how the common diabetes medicine metformin works in people with type 2 diabetes. About 28 participants will take both AZD6793 and a placebo alongside their usual metformin to compare effects on blood sugar levels. The study is currently suspended, and because it is small and early, it is mainly about safety and drug interactions, not a proven new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD6793 (an experimental drug) and metformin (a standard diabetes medication)
What this could lead to
If it works, this could help understand whether AZD6793 can be safely combined with metformin to improve blood sugar control.
What could go wrong
This is a very early Phase 1 trial with only 28 participants, and it is currently suspended. It is designed to check drug interactions, not to prove effectiveness, so results may not lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 28 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Physician-diagnosis of T2DM * On a stable dose of metformin 2000 mg per day for at least 3 months prior to screening. * stable glycaemic control indicated by no change in treatment for diabetes within 3 months prior to screening * HbA1c (Hemoglobin A1c) ≤ 8.5% at screening * Body Mass Index (BMI) within the range 18.5 to 35 kg/m2 , inclusive, at screening. Exclusion Criteria: * Physician diagnosis of type 1 diabetes. * History of any clinically important disease or disorder. * History or presence of chronic Gastrointestinal, hepatic, renal, or pancreatic disease * History of Human immunodeficiency viruses (HIV) infection or a positive HIV test. * History of prior episode(s) of lactic acidosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.